Skip to content

Screening of biomarkers in patients with primary aldosteronism based on clinical and metabonomic data

Screening of biomarkers in patients with primary aldosteronism based on clinical and metabonomic data

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029395
Enrollment
Unknown
Registered
2020-01-29
Start date
2019-09-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary aldosteronism

Interventions

PA group:controll blood pressure
EH group:controll blood pressure

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Persistent hypertension: more than 150/100mmhg blood pressure three times in different days; refractory hypertension: the blood pressure is still more than 140/90mmHg under the treatment of three antihypertensive drugs (including diuretics); only four or more antihypertensive drugs can control the blood pressure below 140/90mmHg; 2) Hypertension with spontaneous hypokalemia or hypokalemia induced by diuretics; 3) Hypertension with adrenal incidentaloma; 4) Hypertension with obstructive sleep apnea; 5) Hypertension patients with family history of early-onset hypertension or family history of early-onset cerebrovascular accident (< 40 years old); 6) The first degree relatives with hypertension were found in PA patients.

Exclusion criteria

Exclusion criteria: 1) Acute and chronic heart, liver and kidney dysfunction; 2) Patients with arrhythmia, stroke, transient ischemic attack, angina pectoris and myocardial infarction; 3) Pregnancy and taking contraceptives, sex hormones or glucocorticoids, non steroidal anti-inflammatory drugs licorice and its preparations; 4)Alcoholic; 5) History of cancer; 6) Secondary hypertension or white coat hypertension with definite etiology; 7) Uncontrolled diabetes, trauma and infection stress.

Design outcomes

Primary

MeasureTime frame
aldosterone;angiotension II;plasma renin activity;cortisol;11-deoxycorticosterone;18-oxycortisol;

Countries

China

Contacts

Public ContactTian Haoming

West China Hospital, Sichuan University

hmtian999@126.com+86 18980601303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026